- Thinly traded nano cap Jaguar Animal Health (NASDAQ:JAGX +5.3%) reports final top-line results from a proof-of-concept study conducted in 2015 assessing Canalevia (crofelemer) for the treatment of secretory diarrhea in dogs. The data showed treatment with crofelemer produced a statistically valid improvement in symptoms compared to placebo.
- The company expects to file a New Animal Drug Application in 2017 seeking approval of Canalevia for the treatment of acute diarrhea in dogs.
- Canalevia is a canine-specific formulation of crofelemer, a botanical drug with anti-secretory properties that is isolated and purified from a tree called Croton lechleri. A formulation for human use is marketed under the brand name Mytesi by Napo Pharmaceuticals.